The POSITIVE trial has been featured in the ASCO Post, highlighting its contribution to advancing evidence on pregnancy after hormone receptor–positive breast cancer. 

 
In the interview, Dr. Ann Partridge discusses the updated findings and their implications for clinical practice, reinforcing the feasibility of temporary interruption of endocrine therapy in carefully selected patients. 
 
This recognition underscores the importance of ongoing research addressing fertility considerations and supports informed decision-making for young patients balancing cancer treatment and family planning.